Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
CRXT was delisted on the 30th of August, 2022.
21 hedge funds and large institutions have $37.6M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$7.04M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$4.99M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$4.03M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2.88M |
| 5 |
MSU
Mizuho Securities USA
New York
|
+$2.86M |
Top Sellers
CRXT Hedge Fund Activity: Q1 2021 in Review
21 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q1 2021, worth a combined $37.6M.
Buyers outnumbered sellers: 21 funds opened new CRXT positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Karpus Investment Management, opening a new position worth an estimated $7.04M.
- 21 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $37.6M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q1 2021.
- 21 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +21 holders.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q1 2021 was Karpus Investment Management, an estimated $7.04M added.
Based on aggregated 13F filings for Q1 2021.